Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686356 | 0.82 | GAA (0.43) | GAANPC1MAPTKMT2AALDH1A1 | |
| SCHEMBL31277237 | 0.78 | CA2 (0.54) | ALDH1A1ACHEPOLBCYP2C9MAPK1 | |
| SCHEMBL470124 | 0.78 | CA2 (0.54) | ALDH1A1ACHEPOLBCYP2C9MAPK1 | |
| SCHEMBL26386327 | 0.77 | CSNK2A1 (0.56) | GAAKMT2AMEN1MAPK1IDO1 | |
| SCHEMBL12326172 | 0.76 | PTGS2 (0.53) | GAANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL196490 | 0.76 | TTR (0.62) | GAANPC1MAPTKMT2AALDH1A1 | |
| SCHEMBL482383 | 0.76 | CA2 (0.41) | ALDH1A1ACHETTR | |
| SCHEMBL29687129 | 0.76 | TTR (0.62) | GAANPC1MAPTKMT2AALDH1A1 | |
| SCHEMBL28075653 | 0.75 | TP53 (0.48) | MAPTKMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL3539341 | 0.74 | ACHE (0.44) | MAPTALDH1A1SMN1; SMN2ALOX15ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| EP-4010333-A1 | PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| EP-3611174-B1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2022-06-08 | — | — | EP | disclosed |
| CN-114206852-A | Plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| CN-109952300-B | 5-or 8-substituted imidazo [1,5-a ] pyridines | 百济神州有限公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-3342765-B1 | CATHEPSIN K INHIBITOR AND APPLICATION THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-107922315-B | Cathepsin K inhibitors and uses thereof | 广东东阳光药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1611123-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004091480-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-4977178-A | Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1990-12-11 | — | — | US | disclosed |
| US-4879391-A | 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents | PFIZER INC. (US) | 1989-11-07 | — | — | US | disclosed |
| US-4861880-A | 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0104860-B1 | 1-PHENYL-2(1H,3H)-INDOLONE PSYCHO-THERAPEUTIC AGENTS | PFIZER INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| US-4476307-A | Heteroylidene indolone compounds | PFIZER INC. (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0104860-A1 | 1-Phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | GAA 151/4885NPC1 1179/4885MAPT 3548/4885 |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | GAA 1452/4885NPC1 1834/4885MAPT 4276/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | GAA 151/4885NPC1 1179/4885MAPT 3548/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | GAA 151/4885NPC1 1179/4885MAPT 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.